|Send to printer »|
Columns : Aug 1, 2012 ( )
People in the News
Bibby Scientific U.S. hired Peter Lucas as president for the western hemisphere. Before this appointment, Lucas served as North American director of marketing, laboratory solutions at Sartorius. He has also worked for Merck KGaA Millipore.
Molecular Partners hired Lisa Rojkjaer, M.D., as CMO...Knome appointed Gary A. Cohen, J.D., as svp and general counsel and Heidi L. Rehm, Ph.D., to its scientific advisory board...Martin Latterich, Ph.D., is now CSO of BioScale...Pressure BioSciences appointed Vito Mangiardi and Kevin Pollack to its newly configured board of directors.
Diffinity Genomics appointed Donald E. Pogorzelski to its board of directors. Pogorzelski was previously president of Genzyme Diagnostics prior to its sale to Sekisui Chemical in 2011. Before joining Genzyme, he was regional marketing manager, Boston region (Northeast) of Abbott Laboratories’ diagnostics division.
Damian Marron is now CEO of Cytheris...Trophos appointed Christine Placet as CEO...to-BBB hired Ajay Mistry, Ph.D., as head of business development...Transgenomic appointed John M. McAuliffe as vp of business development, neurology, and Matthew W. Beer as vp of business development, oncology.
Diffinity Genomics appointed Eric Allyn to its board of directors. Allyn is an owner of Welch Allyn, where he is now co-chairman of its board. Since starting his career there in 1982, he has held various roles including sales management and marketing communications.
ViaCyte named Paul Laikind, Ph.D., CEO...Clarus Therapeutics appointed Bela S. Denes, M.D., as CMO...Louis Kayitalire, M.D., joined BioAlliance Pharma as head of R&D...Xcovery appointed Samuel Broder, M.D., as senior scientific and clinical strategist...Dennis Fenton, Ph.D., is now chairman of Althea Technologies’ scientific advisory board...Nile Therapeutics appointed Darlene Horton, M.D., as its CMO...Oncothyreon promoted Scott Peterson, Ph.D., to CSO.
Sucampo Pharmaceuticals appointed Silvia Taylor as svp, investor relations, public relations, and corporate communications. Taylor previously worked at MedImmune as senior director of marketing, RSV franchise and senior director of marketing, global influenza franchise.
Alnylam Pharmaceuticals appointed Oved Amitay to vp, head of commercial and promoted Akshay Vaishnaw, M.D., Ph.D., to evp and CMO; Jared Gollob, M.D., to vp, clinical research; and Lubomir (Lubo) Nechev, Ph.D., to vp, process sciences...Carolyn Beaver is now vp and CAO of Sequenom...EvaluatePharma named Debbie Paul CEO, Americas...Anavex appointed Robert Chisholm as CFO...Accelr8 Technology hired Lawrence Mehren as president, CEO, and a member of the board of directors.
Macrocure named Nissim Mashiach as president and CEO. Mashiach has worked in the pharmaceutical industry for 25 years, most recently as general manager at Ethicon, a Johnson & Johnson company. He has also served as president and COO at Omrix Biopharmaceuticals.
MethylGene elected Rodney Lappe, Ph.D., to its board of directors...Antares Pharma appointed Jonathan S. Jaffe, M.D., as vp, clinical development...Gen9 appointed Kevin Munnelly as president and CEO...Cleave Biosciences appointed David Wustrow, Ph.D., as vp, chemistry...Ricerca Biosciences appointed G. Lynn Miesel, Ph.D., as technical director...Cubist Pharmaceuticals named Robert J. Perez president and COO, Michael Tomsicek svp and deputy CFO, and Thomas Rollins svp, program and portfolio management.
Scott A. Siegel, Ph.D., has been named COO of Ezose Sciences. Dr. Siegel has worked in the biotechnology and pharmaceutical industries for over 25 years. He joined Ezose in 2009; before that, he was vp, corporate development for Redpoint Bio. He has also worked at Johnson & Johnson.
© 2016 Genetic Engineering & Biotechnology News, All Rights Reserved